Asset: Claudin18.2/CD3 bispecific T-cell engager (TCE)
Development Stage: Clinical stage
Indication: Claudin18.2-positive advanced gastric cancer and pancreatic cancer
Key Asset Highlights:
- Exerts precise anti-tumor mechanism by bridging tumor surface Claudin18.2 and T cell surface CD3, effectively recruiting and activating endogenous T cells to induce sustained lysis and elimination of Claudin18.2-positive tumor cells.
- Delivers robust and durable clinical anti-tumor efficacy in refractory and first-line treatment settings, demonstrating prominent therapeutic benefits for hard-to-treat gastrointestinal tumors with unmet clinical needs.
- Achieves superior synergistic anti-tumor effects in combination with standard chemotherapy regimens, significantly improving tumor response rate and broadening clinical application scenarios.
- Obtained FDA orphan drug designation, with well-established safety and tolerability profiles verified in completed clinical trials, supporting steady advancement of large-scale studies.
- Backed by a comprehensive and robust intellectual property system, securing exclusive global development, clinical promotion and commercialization rights of the product.
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
